Prices delayed by at least 15 minutes | Print
BioMarin Pharmaceutical (BMRN)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Address
770 Lindaro Street
San Rafael
CA
USA
94901
Telephone
+1 415 4557558
Forecast key dates
Name | Key Date |
---|---|
Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 2025 | 2025-04-24T16:30:00 |
Biomarin Pharmaceutical Inc First Quarter Earnings Results for 2025 | 2025-04-24T00:00:00 |
Biomarin Pharmaceutical Inc Annual Report for 2024 | 2025-02-26T00:00:00 |
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-02-21T16:30:00 |
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Results for 2024 | 2025-02-21T00:00:00 |
Biomarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 2024 | 2024-11-01T16:30:00 |
Biomarin Pharmaceutical Inc Third Quarter Earnings Results for 2024 | 2024-11-01T00:00:00 |
Biomarin Pharmaceutical Inc Second Quarter Earnings Conference Call for 2024 | 2024-07-31T16:30:00 |
Biomarin Pharmaceutical Inc Second Quarter Earnings Results for 2024 | 2024-07-31T00:00:00 |
Biomarin Pharmaceutical Inc Annual General Meeting for 2023 | 2024-05-23T10:00:00 |
BioMarin to Present at the BofA Securities 2024 Health Care Conference | 2024-05-15T10:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.